Home » Newsletters » BioWorld Science

BioWorld Science

May 22, 2008

View Archived Issues

Clinical symptom resolution following therapeutic immunization with oral HCV vaccine

Benznidazole clears parasites, induces CD8+ T-cell memory in Chagas' disease model / News in Context

GlaxoSmithKline's avian influenza virus vaccine candidate safe in children

Ribavirin effective in children with Crimean-Congo hemorrhagic fever

SIRT1 activation shows benefit in murine model of COPD

Topigen's novel multitarget antisense oligonucleotides may be useful for the treatment of asthma

Small molecule targeting microtubules and Bcl-2 effective in prostate cancer xenograft model

Advaxis files IND with FDA for phase II Lovaxin C protocol

BioMarin initiates phase I PEG-PAL study in phenylketonuria

GlobeImmune completes planned enrollment for phase II GI-5005 trial in HCV

Myogane receives orphan medicinal product designation from EMEA

Omeros initiates patient enrollment in phase I OMS-201 study

Telik initiates two phase II Telintra studies

Daiichi Sankyo acquires U3 Pharma for EUR 150 million

SIGA completes screen of small-molecule chemical library in dengue fever antiviral program

Osiris Therapeutics initiates dosing in phase II clinical trial of Prochymal in COPD

FivePrime and Pfizer enter collaboration agreement in oncology and diabetes

Merck & Co. discontinues ACHIEVE imaging study of MK-0524A in HeFH

FDA accepts Anesiva's supplemental NDA filing to expand indication for Zingo

NeoPharm initiates enrollment in phase I clinical trial of LE-DT for metastatic solid cancer

Schering-Plough will initiate two phase III studies of boceprevir in HCV genotype 1

Sunesis initiates REVEAL-1 phase II clinical trial of voreloxin in elderly patients with AML

New antiinflammatory agents disclosed in recent Merck and Kyowa Hakko patents

Novel treatments for diabetes described in recent patent literature

Recent patents report new therapeutic agents for obesity and lipoprotein disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...